Localized prostate cancer management has evolved significantly over the past decade. Historically, patients faced a binary choice between active surveillance and radical whole-gland treatment. Radical prostatectomy and whole-pelvis radiotherapy offer established oncologic control. However, both treatments carry risks of urinary incontinence and erectile dysfunction.
Focal therapy has emerged as a middle-ground strategy. This tissue-preserving approach selectively destroys the clinically significant tumor lesion while sparing adjacent healthy parenchyma. Consequently, focal therapy preserves the neurovascular bundles, the external urinary sphincter, and the bladder neck.
This guide examines the clinical criteria, diagnostic prerequisites, comparative trade-offs, and procedural pathways defining focal therapy for localized prostate cancer.
1. What Is Focal Therapy for Prostate Cancer?
Focal therapy treats only the diseased portion of the prostate gland. The biological rationale rests on the “index lesion” hypothesis. Extensive pathology research indicates that the highest-grade dominant tumor focus typically drives disease progression and metastatic risk.
Secondary, low-grade microscopic foci often remain clinically indolent. By precisely ablating the index lesion with an adequate safety margin (typically 5 to 10 mm), clinicians achieve disease control. At the same time, this targeted treatment significantly reduces functional side effects.
2. Patient Selection and Clinical Indication Criteria
Careful patient selection is vital for successful focal ablation. An incomplete ablation of unrecognized lesions can lead to disease recurrence. Therefore, candidates must undergo thorough multiparametric magnetic resonance imaging (mpMRI) and targeted biopsy confirmation.
- Clinical Staging: Organ-confined disease staged as cT1c to cT2a.
- Prostate-Specific Antigen (PSA): Serum PSA generally below 10–15 ng/mL.
- PSA Density (PSAD): Ideally less than 0.15 ng/mL/cm³.
- Histologic Grade Group: Grade Group 2 (Gleason 3+4=7) or select intermediate-risk Grade Group 3 (Gleason 4+3=7).
- Very low or low-risk disease (Grade Group 1, Gleason 6) is usually managed with active surveillance.
- High-risk disease (Grade Group 4 or 5) requires definitive whole-gland intervention.
- Lesion Concordance: The visible target on mpMRI (PI-RADS 4 or 5) must align with positive cores on targeted biopsy.
- Unilateral Disease: Discrete lesion confined to one lobe or hemisphere. Systematic biopsies of the contralateral lobe must confirm the absence of clinically significant prostate cancer (csPCa).
- Life Expectancy: Generally suitable for men with a life expectancy exceeding 10 years who prioritize functional preservation.
3. Treatment Comparison: Focal Therapy vs. Radical Prostatectomy vs. Active Surveillance
Choosing the right approach requires balancing cancer eradication against quality-of-life preservation. The following comparison highlights the clinical profiles of each strategy:
- Focal Therapy (Targeted Ablation)
- Primary Goal: Eradicate the index lesion while preserving normal prostatic architecture and surrounding nerves.
- Continence Preservation: Over 95% to 98% in published clinical trials.
- Potency Preservation: Approximately 80% to 90% return of erectile baseline function.
- Oncologic Monitoring: Requires rigorous longitudinal follow-up, including protocol mpMRI and protocol biopsies.
- Retreatment Rate: Reported between 10% and 25% within 3 to 5 years, which may involve repeat focal ablation or salvage radical therapy.
- Radical Prostatectomy (Robotic-Assisted Laparoscopic Prostatectomy)
- Primary Goal: Complete removal of the entire prostate gland and seminal vesicles.
- Continence Preservation: 80% to 92% long-term recovery, depending on baseline age and anatomy.
- Potency Preservation: 35% to 70% with bilateral nerve-sparing techniques.
- Oncologic Monitoring: Straightforward tracking with ultrasensitive PSA tests (expected nadir < 0.05 ng/mL).
- Retreatment Rate: Biochemical recurrence occurs in 15% to 30% of intermediate-to-high-risk cohorts, requiring salvage radiation.
- Active Surveillance
- Primary Goal: Avoid overtreatment of low-risk, indolent disease while monitoring closely.
- Continence & Potency Preservation: 100% preservation initially, as no physical ablation occurs.
- Oncologic Monitoring: Serial PSA testing, routine clinical exams, serial mpMRI scans, and repeat biopsies.
- Transition Rate: Roughly 30% to 50% of patients transition to definitive treatment within 5 to 10 years due to histologic upgrading.
4. Primary Energy Modalities in Focal Therapy
Different energy sources achieve precise tissue necrosis through thermal, cryotherapeutic, or electrical mechanisms:
- High-Intensity Focused Ultrasound (HIFU)
- Uses transrectally focused acoustic waves to generate rapid hyperthermia (>65°C), causing coagulative necrosis.
- Most effective for posterior and lateral lesions within reach of the transrectal transducer focal depth.
- Cryoablation (Targeted Cryotherapy)
- Employs percutaneous transperineal needles to cycle argon and helium gases, creating temperatures below -40°C.
- Effectively treats anterior and apex lesions while using a urethral warming catheter to protect the urinary tract.
- Irreversible Electroporation (IRE / NanoKnife)
- Delivers high-voltage electrical pulses between micro-electrodes, perforating cell membrane lipid bilayers to cause apoptosis.
- Spares surrounding collagenous structures, vascular architecture, and neural connective tissue sheets.
- Focal Photodynamic Therapy (PDT) and Focal Laser Ablation (FLA)
- Direct interstitial lasers or light-activated photosensitizers produce reactive oxygen species to trigger vascular occlusion and cellular death.
5. Diagnostic Prerequisite: The S-Fusion™ Biopsy Standard
Focal therapy cannot succeed without high diagnostic precision. Traditional transrectal random biopsies miss up to 30% of significant cancers. They also underestimate tumor grade and volume.
Advanced private urology centers in Korea utilize 3D MRI-ultrasound fusion biopsy systems, such as S-Fusion™. This platform merges pre-procedural 3.0T mpMRI sequences with real-time transrectal ultrasound. The system uses artificial intelligence to correct for prostatic deformation during probe movement.
As a result, clinicians obtain pinpoint accuracy within 1 to 2 mm. This accuracy guarantees that the targeted focal ablation margin covers the true tumor perimeter. It also ensures the contralateral lobe remains completely free of significant malignancy.
6. Surveillance Protocol, Failure Scenarios, and Salvage Pathways
Undergoing focal therapy requires structured, lifelong surveillance. Because untreated prostate tissue remains in place, de novo tumors or recurrent lesions can develop over time.
- Post-Procedural PSA Kinetics: PSA levels will drop, but they do not reach undetectable levels like they do after surgery. Clinicians track the PSA nadir and calculate PSA doubling time.
- Multiparametric MRI Schedule: Performed at 6 months post-ablation to assess the treatment zone, and repeated annually thereafter.
- Surveillance Biopsy: A protocol biopsy is recommended between 12 and 24 months. This step samples both the treated margin and untreated tissue, regardless of PSA stability.
- Failure Definitions and Triggers for Escalation:
- In-field Recurrence: Viable cancer persisting inside the treated margin, often due to under-dosing or thermal sink effects near blood vessels.
- Out-of-field Progression: New high-grade tumors developing in previously untreated zones of the gland.
- Rising PSA Kinetics: Consecutive PSA rises meeting the Phoenix criteria (nadir + 2.0 ng/mL) or showing rapid doubling times (<12 months).
- Salvage Pathways:
- Repeat Focal Ablation: Applicable if recurrence is localized, unifocal, and within intermediate risk.
- Salvage Radical Prostatectomy: Surgically removes the gland. It is technically more demanding due to periprostatic fibrosis, but it remains fully viable.
- Salvage Stereotactic Body Radiotherapy (SBRT): Highly effective non-surgical radiation backup for bilateral or multi-focal relapses.
7. Complications and Red Flag Symptoms
While focal therapy is less invasive than radical surgery, tissue ablation still causes local inflammation and temporary edema. Patients should recognize normal healing symptoms versus clinical red flags:
- Expected Post-Procedural Symptoms:
- Mild dysuria and minor terminal hematuria for 1 to 2 weeks.
- Temporary urinary frequency or urgency caused by urethral proximity irritation.
- Passage of small necrotic tissue sloughs during urination.
- Clinical Red Flags Requiring Immediate Escalation:
- High fever (>38.3°C / 101°F) accompanied by chills, signaling acute prostatitis or urosepsis.
- Acute urinary retention with painful bladder distension, necessitating clean intermittent catheterization.
- Continuous gross hematuria with thick blood clots that block voiding.
- Persistent perineal or pelvic pain unresponsive to prescribed oral analgesics.
8. Estimated Diagnostic and Pre-Treatment Costs in Korea
International patients often seek precision prostate diagnostics and tissue-preserving evaluations in Korea. The country offers advanced medical infrastructure and short wait times. Below are the estimated outpatient and diagnostic costs, based on multi-center benchmark data:
- Initial Specialist Urological Consultation: Approx. ₩27,000 (~$20 USD; range ₩10,000–₩50,000)
- Follow-Up Consultation: Approx. ₩23,000 (~$17 USD; range ₩10,000–₩50,000)
- In-House Serum PSA Blood Test: Approx. ₩35,000 (~$26 USD)
- Transrectal Ultrasound of the Prostate (TRUS): Approx. ₩184,000 (~$136 USD; range ₩156,000–₩220,000)
- Uroflowmetry and Post-Void Residual (PVR) Evaluation: Approx. ₩93,000 (~$69 USD)
- AI-Guided MR-Ultrasound Fusion Targeted Biopsy (e.g., S-Fusion™): Approx. ₩3,000,000 (~$2,222 USD)
- (Clinical Disclaimer: Estimated costs reflect representative clinic averages in Korea. Final charges vary based on lesion complexity, pathology staining requirements, anesthesia type, and inpatient observation needs. Comprehensive pricing is confirmed following an initial clinical examination.)